|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 182.70 USD | +0.33% |
|
-0.25% | -12.89% |
| 02:16pm | ICON plc Releases Findings from Two Biotech Sector Survey | CI |
| 12-02 | Icon survey reveals increasing clinical trial startup delays | RE |
| Capitalization | 13.91B 11.95B 11.21B 10.44B 19.23B 1,249B 20.9B 130B 50.52B 592B 52.18B 51.07B 2,182B | P/E ratio 2025 * |
28.2x | P/E ratio 2026 * | 19x |
|---|---|---|---|---|---|
| Enterprise value | 16.93B 14.54B 13.64B 12.71B 23.41B 1,521B 25.44B 158B 61.5B 721B 63.52B 62.17B 2,656B | EV / Sales 2025 * |
2.1x | EV / Sales 2026 * | 2.02x |
| Free-Float |
99.29% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: ICON Public Limited Company
| 1 day | +0.54% | ||
| 1 week | -0.10% | ||
| Current month | -1.10% | ||
| 1 month | +16.03% | ||
| 3 months | +8.30% | ||
| 6 months | +30.96% | ||
| Current year | -12.76% |
| 1 week | 174.13 |  | 191.15 |
| 1 month | 154.12 | | 191.15 |
| Current year | 125.1 | | 228.28 |
| 1 year | 125.1 | | 228.28 |
| 3 years | 125.1 | | 347.72 |
| 5 years | 125.1 | | 347.72 |
| 10 years | 62.31 | | 347.72 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Director of Finance/CFO | 52 | 30/09/2024 | |
Tom O'Leary
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Chief Administrative Officer | 50 | 30/06/2016 |
| Director | Title | Age | Since |
|---|---|---|---|
John Climax
CHM | Chairman | 72 | 31/10/2002 |
Ciaran Murray
CHM | Chairman | 62 | 28/02/2017 |
Stephen Cutler
BRD | Director/Board Member | 64 | 24/11/2015 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 0.91% | 4 M€ | +21.65% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.56% | -0.10% | -16.54% | -6.06% | 13.91B | |
| -1.28% | -2.24% | +4.39% | +18.43% | 47.68B | |
| -1.49% | -2.45% | +6.62% | +5.55% | 38.07B | |
| -1.19% | -2.38% | +55.25% | +63.62% | 36.13B | |
| +0.11% | +0.81% | +13.57% | +20.52% | 27.89B | |
| -0.12% | -6.33% | +55.23% | +165.70% | 15.47B | |
| -2.19% | +3.97% | +66.45% | +229.27% | 15.48B | |
| -1.53% | +2.50% | +63.05% | - | 13.71B | |
| -1.90% | -1.81% | +106.95% | +112.91% | 13.2B | |
| -4.12% | -1.07% | +51.03% | +70.83% | 12.65B | |
| Average | -1.31% | -0.19% | +40.60% | +75.64% | 23.42B | |
| Weighted average by Cap. | -1.20% | -0.63% | +31.65% | +56.13% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 8.08B 6.94B 6.51B 6.07B 11.17B 726B 12.14B 75.49B 29.34B 344B 30.31B 29.66B 1,267B | 8.13B 6.98B 6.55B 6.1B 11.24B 730B 12.21B 75.96B 29.52B 346B 30.49B 29.85B 1,275B |
| Net income | 556M 478M 449M 418M 770M 49.99B 836M 5.2B 2.02B 23.7B 2.09B 2.04B 87.31B | 726M 624M 586M 546M 1B 65.27B 1.09B 6.79B 2.64B 30.94B 2.73B 2.67B 114B |
| Net Debt | 3.02B 2.6B 2.44B 2.27B 4.18B 272B 4.54B 28.25B 10.98B 129B 11.34B 11.1B 474B | 2.52B 2.17B 2.03B 1.89B 3.49B 226B 3.79B 23.56B 9.16B 107B 9.46B 9.26B 395B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 09/12/25 | 182.68 $ | +0.32% | 249,409 |
| 08/12/25 | 182.10 $ | -2.03% | 1,030,620 |
| 05/12/25 | 185.87 $ | +0.05% | 905,324 |
| 04/12/25 | 185.77 $ | -1.07% | 1,654,494 |
| 03/12/25 | 187.78 $ | +2.53% | 1,031,248 |
Delayed Quote Nasdaq, December 09, 2025 at 05:12 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ICLR Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition